Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market se

SUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leade

BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.13) per share which beat the analyst consen

SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of

LUNR, GLDG and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2026.

Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's

Gainers Exicure (NASDAQ:XCUR) stock rose 38.4% to $2.38 during Tuesday's after-market session.

AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026.

Dear Fellow Shareholders,Upon completion of our recent capital raise, I am providing this update on

SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leade

BioCardia (BCDA) stock slides after a $4.4M share dilution, but analysts spot massive upside. Check

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy an

Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA

Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA

BioCardia Inc. (NASDAQ:BCDA) stock is up on Friday as the company is confirming progress toward pote

BioCardia stock breaks above its 200-day moving average on huge FDA news. Can BCDA clear the $1.50 r

BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the t

SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leade

Results presented by Dr. Raval, on behalf of the CardiAMP CMI Investigators, showed that the minimal

– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally deliver

BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.21) per share which missed the analyst cons

SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader

SUNNYVALE, Calif. , May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a developer of

BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the tr

SUNNYVALE, Calif. , May 08, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader

SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global lead

BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the tr

NEW YORK--(BUSINESS WIRE)--Tamboran Resources Corporation (NYSE: TBN, ASX: TBN): Tamboran Resources

BioCardia (NASDAQ: BCDA) executives on Tuesday outlined new clinical data for the company's lead cel

BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.06) per share which beat the analyst consen

SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leade

BioCardia has had preliminary meetings with both FDA Center for Devices and Radiological Health (CDR

BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatme

BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatm

BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.24) per share which beat the analyst consen

This prospectus supplement updates and amends certain information in our base prospectus, dated Dece

BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatme

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy an